Antiepileptic drug therapy for adults: When to initiate and how to choose

Mayo Clinic Proceedings

Volumn 77, Issue 12, 2002, Pages 1367-1375

  Sirven, Joseph I ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CLONAZEPAM; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADULT; AGITATION; APLASTIC ANEMIA; ATAXIA; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; COGNITIVE DEFECT; CONCENTRATION LOSS; CONFERENCE PAPER; DIPLOPIA; DISEASE CONTROL; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; EPILEPSY; FATIGUE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HAIR LOSS; HEADACHE; HIRSUTISM; HUMAN; HYPONATREMIA; HYPOTENSION; INSOMNIA; LIVER FAILURE; LYMPHADENOPATHY; MEMORY DISORDER; MENSTRUATION DISORDER; NYSTAGMUS; OSTEOPOROSIS; PHARMACOKINETICS; PROPHYLAXIS; RASH; RECURRENT DISEASE; RESPIRATION DEPRESSION; RISK FACTOR; SEDATION; SEIZURE; SOMNOLENCE; TERATOGENICITY; TREMOR; VERTIGO; WEIGHT REDUCTION;

EID: 0036895938     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/77.12.1367     Document Type: Conference Paper

References (48)

1. Kirby S, Sadler RM. Injury and death as a result of seizures. Epilepsia. 1995;36:25-28.
2. Nashef L, Fish DR, Garner S, Sander JW, Shorvon SD. Sudden death in epilepsy: A study of incidence in a young cohort with epilepsy and learning difficulty. Epilepsia. 1995;36:1187-1194.
3. Gowers WR. Epilepsy and Other Chronic Convulsive Diseases: Their Causes, Symptoms & Treatment. New York, NY: William Wood & Co; 1885.
4. Hauser WA, Hesdorffer DC. Epilepsy: Frequency, Causes and Consequences. New York, NY: Demos; 1990.
5. Camfield PR, Camfield CS, Dooley JM, Tibbles JA, Fung T, Garner B. Epilepsy after a first unprovoked seizure in childhood. Neurology. 1985;35:1657-1660.
6. Hopkins A, Garman A, Clarke C. The first seizure in adult life: Value of clinical features, electroencephalography, and computerised tomographic scanning in prediction of seizure recurrence. Lancet. 1988;1:721-726.
7. Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: A quantitative review. Neurology. 1991;41:965-972.
8. Shinnar S, Berg AT, Moshe SL, et al. Risk of seizure recurrence following a first unprovoked seizure in childhood: A prospective study. Pediatrics. 1990;85:1076-1085.
9. Annegers JF, Shirts SB, Hauser WA, Kurland LT. Risk of recurrence after an initial unprovoked seizure. Epilepsia. 1986;27:43-50.
10. Shinnar S, Berg AT, Moshe SL, et al. The risk of seizure recurrence after a first unprovoked afebrile seizure in childhood: An extended follow-up. Pediatrics. 1996;98(2, pt 1):216-225.
11. Mattson RH, Cramer JA, Collins JF, Department of Veterans Affairs Epilepsy Cooperative Studies No. 118 and No. 264 Group. Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures. Neurology. 1996;47:68-76.
12. Gilad R, Lampl Y, Gabbay U, Eshel Y, Sarova-Pinhas I. Early treatment of a single generalized tonic-clonic seizure to prevent recurrence. Arch Neurol. 1996;53:1149-1152.
13. First Seizure Trial Group. Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. Neurology. 1993;43(3, pt 1):478-483.
14. Camfield P, Camfield C, Dooley J, Smith E, Garner B. A randomized study of carbamazepine versus no medication after a first unprovoked seizure in childhood. Neurology. 1989;39:851-852.
15. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondary generalized tonic-clonic seizures. N Engl J Med. 1985; 313:145-151.
16. Beghi E, Berg AT, Hauser WA. Treatment of single seizures. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Vol 2. Philadelphia, Pa: Lippincott-Raven Publishers; 1998:1287-1294.
17. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54:1886-1893.
18. Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med. 1990;323:497-502.
19. Rhoney DH, Tipps LB, Murry KR, Basham MC, Michael DB, Coplin WM. Anticonvulsant prophylaxis and timing of seizures after aneurysmal subarachnoid hemorrhage. Neurology. 2000;55:258-265.
20. Mattson RH, Cramer JA, Collins JF, Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med. 1992;327:765-771.
21. Theodore WH, Porter RJ. Epilepsy: 100 Elementary Principles. 3rd ed. London, England: WB Saunders Co; 1995.
22. Sirven JI. Acute and chronic seizures in patients older than 60 years. Mayo Clin Proc. 2001;76:175-183.
23. Bourgeois B, Leppik IE, Sackellares JC, et al. Felbamate: A double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology. 1993;43:693-696.
24. Sachdeo R, Kramer LD, Rosenberg A, Sachdeo S. Felbamate monotherapy: Controlled trial in patients with partial onset seizures. Ann Neurol. 1992;32:386-392.
25. Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial-onset seizures: An active-control trial. Neurology. 1993; 43:688-692.
26. Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med. 1993;328:29-33.
27. Felbatol (Felbamate) [Clinical Update]. Cranbury, NJ: Wallace Laboratories; 1994.
28. Ben-Menachem E. Expanding antiepileptic drug options: Clinical efficacy of new therapeutic agents. Epilepsia. 1996;37(suppl 2):S4-S7.
29. Anhut H, Ashman PJ, Feuerstein TJ, Quebe-Fehling E, Saunders M, Baron BA, International Gabapentin Study Group. Long-term safety and efficacy of gabapentin (neurontin) as add-on therapy in patients with refractory partial seizures. J Epilepsy. 1995;8:44-50.
30. US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: A double-blind, placebo-controlled, parallel-group study. Neurology. 1993;43:2292-2298.
31. Matsuo F, Bergen D, Faught E, et al, US Lamotrigine Protocol 0.5 Clinical Trial Group. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology. 1993;43:2284-2291.
32. Levetiracetam (Keppra) [Package Insert]. Smyrna, Ga: UCB Pharma; January 2000.
33. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial. Neurology. 2000;55:236-242.
34. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P, European Levetiracetam Study Group. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia. 2000;41:1179-1186.
35. Ben-Menachem E, Falter U, European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia. 2000; 41:1276-1283.
36. Oxcarbazepine (Trileptal) [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2000.
37. Lott RS, Helmboldt K. Oxcarbazepine: A carbamazepine analogue for partial seizures in adults and children with epilepsy. Formulary. 2000;35:219-230.
38. Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: Double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology. 1999;52:732-737.
39. Tiagabine (Gabitril) [Package Insert]. Abbott Park, III: Abbott Laboratories; August 1999.
40. Uthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures: A randomized, add-on, dose-response trial. Arch Neurol. 1998;55:56-62.
41. Sachdeo RC, Leroy RF, Krauss GL, et al, Tiagabine Study Group. Tiagabine therapy for complex partial seizures: A dose-frequency study. Arch Neurol. 1997;54:595-601.
42. Kalvianen R, Brodie MJ, Duncan J, Chadwick D, Edwards D, Lyby K, Northern European Tiagabine Study Group. A double-blind, placebo-controlled trial of tiagabine given three-times daily as addon therapy for refractory partial seizures. Epilepsy Res. 1998;30:31-40.
43. Perucca E. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Epilepsia. 1996;37(suppl 2):S8-S13.
44. Bourgeois BF. Drug interaction profile of topiramate. Epilepsia. 1996;37(suppl 2):S14-S17.
45. Shorvon SD. Safety of topiramate: Adverse events and relationships to dosing. Epilepsia. 1996;37(suppl 2):S18-S22.
46. Zonisamide (Zonegran) [Package Insert]. South San Francisco, Calif: Elan Pharmaceuticals; March 2000.
47. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: A European double-blind trial. Epilepsy Res. 1993;15:67-73.
48. Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson RH. New antiepileptic drugs: Comparison of key clinical trials. Epilepsia. 1999;40:590-600.